The Medical Advisor

Introduction Fenbendazole, a medication traditionally used as an anti-parasitic in veterinary medicine, is gaining unexpected attention for its potential benefits in treating chronic inflammatory and autoimmune conditions such as Multiple Sclerosis (MS), Rheumatoid Arthritis, and Osteoarthritis. While research on its use in humans remains limited and largely under the radar, emerging animal studies and personal testimonials suggest that fenbendazole and ivermectin—may offer significant relief for patients struggling with these debilitating diseases. This post explores the scientific background, shares compelling case reports, and highlights the growing interest in repurposing these medications for conditions far beyond their original scope. Fenbendazole for Multiple Sclerosis Is there any research on the utility of the anti-parasitic Fenbendazole in Multiple Sclerosis? Yes, but it's very well hidden, and you've likely never heard of it. I'll be honest, I hadn...

Fenbendazole for Multiple Sclerosis Is there any research on the utility of the anti-parasitic Fenbendazole in Multiple Sclerosis? Yes, but it's very well hidden, and you've likely never heard of it. I'll be honest, I hadn't either. There is a 2010 paper by Australian Researchers led by A A Ramp: " Strain-related effects of fenbendazole treatment on murine experimental autoimmune encephalomyelitis ". Dr William Makis  posted  on X/Twitter: What is murine experimental autoimmune encephalomyelitis? Animal model of Multiple Sclerosis! "FBZ is delivered orally by premixing into rodent chow at a rate of 150 mg/kg of diet. This assumes an average daily food intake of 8 mg/kg body weight, sufficient to ensure a therapeutic dose". Rodent chow. Sounds delicious. FENBENDAZOLE decreased # of sick mice from 99% to 38.6% in one MS disease model (NOD/LtJ) FENBENDAZOLE decreased # of sick mice from 99% to 62.5% in another MS disease model (C57BL/6J) These ar...

Low-dose naltrexone (LDN) is generating buzz as a potential treatment for a range of conditions, from chronic pain to autoimmune disorders, offering new hope for patients with difficult-to-manage symptoms. While hailed for its symptom relief, some health experts warn that LDN may not tackle the underlying causes of disease. The question remains: Is this affordable, underutilized drug a breakthrough or merely a temporary fix? A Lifeline Linda Elsgood felt unstoppable. A mother of two and full-time bank manager, she balanced work and family with ease. “I was Wonder Woman. I could do anything,” she told The Epoch Times. But when both her parents fell ill, the stress of caregiving began to take its toll. Soon after, Elsgood began experiencing troubling symptoms: numbness in her leg and face, extreme fatigue, and vision issues. In 2000, she was diagnosed with relapsing-remitting multiple sclerosis (MS). By 2003, the disease had progressed to secondary progressive MS, and her doctors informe...